From: Design of a trial evaluating myocardial cell protection with cariporide, an inhibitor of the transmembrane sodium-hydrogen exchanger: the Guard During Ischemia Against Necrosis (GUARDIAN) trial
Total
UA/NSTEMI
PCI
CABG
Enrolment
   Projected
9 000
40-50%
20-35%
10-20%
   Actual*
11 590
45%
30%
25%
Event rate
13.12%
10-15%
20-25%
   Actual
12.95%
12.72%
10.91%
15.78%